RecruitingEN originalGastric cancer

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Pacjent z potwierdzonym zapaleniem przełyku Barretta (widocznym podczas badania endoskopowego)
  • Pacjent z nowotworem przełyku
  • Krewny pacjenta z zapaleniem przełyku Barretta lub nowotworem przełyku
  • Wiek 18 lat lub więcej
  • Wiek poniżej 18 lat - ze zgodą rodzica lub opiekuna
  • Zdolność do wyrażenia świadomej zgody na udział w badaniu

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 10, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (10)

Johns Hopkins Hospital

Baltimore, United States

Mayo Clinic

Rochester, United States

Washington University School of Medicine

St Louis, United States

Columbia University Medical Center

New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, United States

University Hospitals of Cleveland

Cleveland, United States

Cleveland Clinic

Cleveland, United States

University of Pennsylvania

Philadelphia, United States

VA Puget Sound Health Care System

Seattle, United States

Fred Hutchinson Cancer Research Center, UWMC

Seattle, United States

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.